Document is current

Article History

Received: 18 November 2025

Accepted: 3 March 2026

First Online: 19 March 2026

Declarations

:

: The study was conducted in accordance with the Danish Code of Conduct for Research Integrity, approved by the Research Ethics Committee at the University of Southern Denmark (SDU), and complied with the Danish Data Protection Act and the General Data Protection Regulation (GDPR; EU 2016/679). As this study used fully anonymized survey data, no additional ethics approval was required. The study was conducted in accordance with the principles of the Declaration of Helsinki. Informed consent was obtained from all participants prior to their participation in the survey. Participation in the COH-FIT survey was voluntary, and all respondents participated anonymously. Because no identifiable information was collected, individual responses could not be traced back to participants after submission. Consequently, withdrawal of consent or removal of submitted data was not possible.

: Participants provided informed consent for publication of anonymised and aggregated data prior to participating in the survey.

: MS received honoraria/has been a consultant for Angelini, AbbVie, Boehringer Ingelheim, Lundbeck, Otsuka. CUCl has been a consultant and/or advisor to or has received honoraria from: AbbVie, Alkermes, Allergan, Angelini, Aristo, Autobahn, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Draig, Eli Lilly, Eumentis Therapeutics, Gedeon Richter, GH, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, MedLink, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neuraxpharm, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, PPD Biotech, Recordati, Relmada, Response Pharmaeutical, Reviva, Rovi, Saladax, Sanofi, Seqirus, Servier, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Terran, Tolmar, Vertex, Viatris and Xenon Pharmaceuticals. He provided expert testimony for Janssen, Lundbeck and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, IntraCellular Therapies, Relmada, Reviva, Rovi. He has received grant support from Boehringer-Ingelheim, Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, MedLink Global, Mindpax, Quantic, Terran.